Copyright
©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Aug 6, 2020; 8(15): 3142-3155
Published online Aug 6, 2020. doi: 10.12998/wjcc.v8.i15.3142
Published online Aug 6, 2020. doi: 10.12998/wjcc.v8.i15.3142
Recent advances in the management of gastrointestinal stromal tumor
Monjur Ahmed, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Thomas Jefferson University, Philadelphia, PA 19107, United States
Author contributions: Ahmed M solely contributed to the work.
Conflict-of-interest statement: None to declare.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Monjur Ahmed, FACG, FACP, FASGE, FRCP, MD, Associate Professor, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Thomas Jefferson University, 132 South 10th Street, Main Building, Suite 468, Philadelphia, PA 19107, United States. monjur.ahmed@jefferson.edu
Received: March 25, 2020
Peer-review started: March 25, 2020
First decision: May 9, 2020
Revised: May 26, 2020
Accepted: July 14, 2020
Article in press: July 14, 2020
Published online: August 6, 2020
Processing time: 133 Days and 17.4 Hours
Peer-review started: March 25, 2020
First decision: May 9, 2020
Revised: May 26, 2020
Accepted: July 14, 2020
Article in press: July 14, 2020
Published online: August 6, 2020
Processing time: 133 Days and 17.4 Hours
Core Tip
Core tip: Gastrointestinal stromal tumors are increasingly being diagnosed in our clinical practice with the availability of various imaging, endoscopic and endosonographic studies. Now we have better understanding of the pathophysiology of this tumor. A new tyrosine kinase inhibitor is now approved for the treatment of this tumor refractory to other agents in the same class. There is an increased interest in endoscopic resection of this tumor. Updated recommendation for the management of gastrointestinal stromal tumors will also be discussed in this review.